Evan Ya-Wen Yu, MD, provides his insights into the evolving management of patients with castration-resistant prostate cancer (CRPC) and the implications of the genomic landscape on CRPC. Since clinical trial evidence does not clearly inform sequencing strategies, Dr. Yu weaves his insight into this conundrum using 3 cases, with suggestions to help the urologist individualize treatment. The efficacy and safety of near-horizon investigational agents such as poly ADP ribose polymerase inhibitors and programmed death ligand-1 blocking agents are discussed.
- National Comprehensive Cancer Network guidelines on prostate cancer
- Clinical trials such as IMPACT, COU-AA-301 and -302, PREVAIL, PLATO, ALSYMPCA, AFFIRM, TROPIC, PROSELICA, FIRSTANA
- Prechemotherapy vs post-chemotherapy
- Genomic landscape
This activity was developed for urologists, oncologists, and other health care professionals who have an interest in castration-resistant prostate cancer (CRPC).
This activity is supported by an independent educational grant from AbbVie and Sanofi Genzyme.
Evan Ya-Wen Yu, MD
Professor, Department of Medical Oncology
University of Washington School of Medicine
Member, Fred Hutchinson Cancer Research Center
Assistant Fellowship Director, Hematology and Oncology
Fellowship Training Program
University of Washington and Fred Hutchinson Cancer Research Center
Clinical Trials Core Director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance